80%Confidence
0Views
FDASource
2026-04-11Date
Summary
Macleods Pharma's Class II recall for subpotent Levothyroxine Sodium tablets suggests manufacturing issues that could affect patient treatment efficacy. This may lead to regulatory penalties and erode trust in the brand, impacting sales in the competitive thyroid medication market.
Actionable: Assess Macleods' supply chain for further quality risks and consider diversifying thyroid medication sources.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now